Northern Trust Corp Has $9.47 Million Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Northern Trust Corp raised its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 5.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,054,365 shares of the biotechnology company’s stock after purchasing an additional 58,676 shares during the quarter. Northern Trust Corp owned 0.74% of Aurinia Pharmaceuticals worth $9,468,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC grew its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares in the last quarter. Natixis bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $49,000. Blue Trust Inc. increased its position in shares of Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $90,000. Institutional investors own 36.83% of the company’s stock.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, insider Greg Keenan sold 12,239 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the sale, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. The trade was a 7.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the sale, the chief operating officer now owns 739,456 shares of the company’s stock, valued at $5,915,648. This trade represents a 8.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock worth $2,753,094 over the last three months. Company insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $8.19 on Friday. The firm has a market capitalization of $1.11 billion, a PE ratio of -54.60 and a beta of 1.16. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12-month low of $5.11 and a 12-month high of $10.67. The firm has a 50-day moving average price of $8.02 and a 200 day moving average price of $8.24.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to analysts’ expectations of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. Research analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.